| | 1009298-09-2 Basic information More.. |
| Product Name: | AZD-8055 | | Synonyms: | AZD 8055 [5-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol;AZD8055, >=98%;Propanoic acid, 2,2-dimethyl-, [5-(2,4-dichloropyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl]methyl ester;(5-{2,4-dichloropyrido[2,3-d]pyriMidin-7-yl}-2-Methoxyphenyl)Methyl 2,2-diMethylpropanoate;[5-[2,4-Bis((3S)-3-MethylMorpholin-4-yl)pyrido[;5-[2,4-Bis[(3S)-3-Methyl-4-Morpholinyl]pyrido[2,3-d]pyriMidin-7-yl]-2-MethoxybenzeneMethanol;CCG 168;AZD8055,AZD-8055 | | CAS: | 1009298-09-2 | | MF: | C25H31N5O4 | | MW: | 465.54 | | EINECS: | | | Mol File: | 1009298-09-2.mol |  |
Use
A potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. It inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphoryla
tion of the mTORC2 substrate AKT and downstream proteins. The rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1 were fully inhibited by AZD8055, resulting in significant inhibition of cap-dep
endent translation. In vitro, AZD8055 potently inhibits proliferation and induces autophagy in H838 and A549 cells. In vivo, AZD8055 induces a dose-dependent pharmacodynamic effect on phosphorylated S
6 and phosphorylated AKT at plasma concentrations leading to tumor growth inhibition.
- AZD-8055
-
- US $7.00 / KG
- 2019-09-02
- CAS:1009298-09-2
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: JD 495
- AZD-8055
-
- US $2.00 / kg
- 2019-07-06
- CAS:1009298-09-2
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
|
1009298-09-2
Recommend Suppliers |
|